GET DAILY SIGNALSAbCellera Biologics (ABCL) Consolidates After -6% Pullback Following +190% Annual Advance
Key Takeaways
- AbCellera Biologics (ABCL) shares have pulled back roughly 6% over the trailing 30 days, easing from a closing price near $12.61 in mid-October to about $11.82, a consolidation after a steep multi-month advance.
- The defining catalyst of 2026 has been positive Phase 2 data for ABCL635, an investigational antibody for non-hormonal treatment of menopausal vasomotor symptoms, announced in August.
- Third-quarter 2026 results, reported on November 9, beat expectations, with a narrower net loss and revenue that exceeded consensus estimates by a wide margin.
- The company maintains a strong balance sheet, with available liquidity of roughly $890 million following a $200 million equity raise.
- AbCellera continues to build its T-cell engager (TCE) platform through collaborations with AbbVie (ABBV), Jazz Pharmaceuticals (JAZZ), and Vertex Pharmaceuticals (VRTX).
- For additional detail, explore AbCellera's Price Targets, Earnings, and Forecast pages.
Current Market Snapshot
AbCellera Biologics (ABCL) has been one of the more notable movers in the biotechnology sector over the past year, advancing more than 190% over the trailing 52 weeks and climbing well above its 52-week low of $2.75. That powerful rally has recently shifted into a period of consolidation, with the stock trading in a range between roughly $11 and $13 during October and early November. The pullback of about 6% over the last 30 days leaves shares near $11.82, below their 50-day moving average of approximately $12.33 but still far above the 200-day moving average near $7.16, reflecting a market that is digesting gains rather than reversing the broader uptrend. Analyst sentiment remains constructive, with a consensus "Strong Buy" rating and an average price target around $18. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
AbCellera Biologics (ABCL) Business Overview and Competitive Position
AbCellera Biologics (ABCL) is a clinical-stage biotechnology company headquartered in Vancouver, Canada, focused on discovering and developing first-in-class antibody-based medicines across endocrinology, women's health, immunology, oncology, and other therapeutic areas. The company built its reputation on a full-stack antibody discovery engine that combines single-cell analysis, protein engineering, and machine learning to identify therapeutic antibody candidates for partners. In recent years, AbCellera has sharpened its focus on advancing its own internal pipeline while continuing to monetize its discovery platform through partnerships. Its T-cell engager platform, which supports the engineering of multispecific antibodies, has become a central pillar of the business, attracting collaborations with major pharmaceutical companies. Investors follow the stock for its combination of a differentiated discovery capability, a growing internal clinical pipeline, and a cash-rich balance sheet that funds multi-year development without immediate financing pressure.
Recent Developments Driving ABCL
The most significant recent catalyst for AbCellera was the positive top-line Phase 2 data for ABCL635, announced on August 10, 2026. The study evaluated a single 600-milligram injection in women with moderate to severe vasomotor symptoms, or hot flashes, due to menopause. Results showed a placebo-adjusted reduction in hot-flash frequency of 50% at four weeks and a 46% placebo-adjusted reduction in severity, with complete resolution of moderate-to-severe events in 37% of treated patients versus 2.2% on placebo. Management has described the dataset as potentially category-defining and has committed to advancing ABCL635 into late-stage development in 2027.
On the financial side, third-quarter 2026 results reported November 9 exceeded consensus expectations, with revenue of $10.64 million versus an estimate near $5.43 million and a net loss that narrowed year over year. A $200 million equity raise lifted available liquidity to roughly $890 million, providing runway for the company's clinical plans. Business development momentum has also continued, building on the company's TCE collaborations with Jazz Pharmaceuticals and Vertex, which together added more than $110 million in near-term upfront payments and carry substantial potential downstream milestones and royalties.
2026 Outlook and What Investors Should Watch
Looking ahead, the primary driver for AbCellera remains the clinical and regulatory trajectory of ABCL635. Investors will be watching for the finalization of pivotal trial design, including dose, comparator, and sample size, as well as updates on manufacturing scale-up and longer-term safety data such as repeat-dose immunogenicity. The company has also guided toward late-stage development in menopausal VMS during 2027, along with additional studies in cancer-treatment-related hot flashes. Beyond ABCL635, the advancement of ABCL992, ABCL386, and ABCL688 toward the clinic, and any new business development activity on the TCE platform, represent additional catalysts. Macroeconomic conditions and sector-wide sentiment toward pre-revenue biotech companies may continue to influence trading, as may the pace of cash utilization relative to the company's stated multi-year runway. As with any clinical-stage biotech, trial outcomes and regulatory decisions carry inherent uncertainty and remain the key risks to monitor. From what I see, monitoring these milestones closely will be essential in the months ahead.
Using AI Tools to Track Biotech Opportunities
In my analysis of names like AbCellera Biologics (ABCL), I often turn to Tickeron’s AI Daily Buy/Sell Signals to get a data-driven view of momentum across similar stocks. This approach helps surface patterns that might otherwise go unnoticed in a fast-moving sector. It complements traditional research without replacing it, offering another lens on potential entry or exit points based on automated signals.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.
ABCL sees its Stochastic Oscillator climbs out of oversold territory
On November 05, 2026, the Stochastic Oscillator for ABCL moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 65 instances where the indicator left the oversold zone. In 53 of the 65 cases the stock moved higher in the following days. This puts the odds of a move higher at over 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +12.31% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABCL advanced for three days, in 207 of 255 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ABCL as a result. In 78 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
The Moving Average Convergence Divergence Histogram (MACD) for ABCL turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 35 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.
ABCL moved below its 50-day moving average on November 11, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ABCL crossed bearishly below the 50-day moving average on November 02, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 77%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABCL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
ABCL broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ABCL entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.296) is normal, around the industry mean (3.498). P/E Ratio (-22.000) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (53.191) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. ABCL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABCL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement